Replies to post #197315 on Avid Bioservices Inc (CDMO)

[corporalagarn]

Does this have anything to do with PPHM in any way?

Thanks.

[biopharm]

Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL :

ok... MDSC's and Dmitry Gabrilovich go hand in hand and he is the expert on Myeloid Derived Suppressor Cells and how the cascade of events (Notch Signaling type of events..) say "increased MDSC's" is very bad and leads to inflammation and inflammation leads to cancer.

Now... we have "BI" talking MDSC's, specifically targeting MDSC's ??? but hey.... maybe they are really targeting flipped PS and are only seeing changes re: MDSC's ?

Lets go Peregrine legal.... get on the many cases that are in a round a bout way not trying to say they are targeting flipped PS but they don't ?? Instead more than a few biotechs are now coming out saying MDSC's is the key.... but PS Targeting should be the key!... and the effect of targeting flipped PS is decreased MDSC's, increased TAM's, dendritic cells..etc which is all just part of the Notch signaling pathway.

Now we should see why we have Dr. Dmitry Gabrilovich as a leading KOL of MDSC's because I'm sure he would straight out say it is not MDSC's that are being targeted.

or... this is just part of the game and slowly bringing PS Targeting to the surface.

--------------------

BOEHRINGER INGELHEIM’S
ONCOLOGY ASH 2014

Dec 8, 2014

Abstract #4597: Novel Therapeutic
Approach to Improve Hematopoiesis By
Targeting Myeloid Derived Suppressor Cells
with a Humanized Anti-CD33 Antibody
Poster Session 636 | 6:00-8:00 PM
(PST)
West Building, Level 1 (Moscone Center)
Erika A Eksioglu, Ph.D.

Abstract #4681: BI 836826, a Novel
Fc-Engineered Antibody in Combination
with Phosphoinositide-3-Kinase Inhibitor
for Treatment of High Risk Chronic
Lymphocytic Leukemia
Poster Session 642 | 6:00-8:00 PM
(PST)
West Building, Level 1 (Moscone Center)
Deborah M Stephens, D.O.

http://us.boehringer-ingelheim.com/content/dam/internet/opu/us_EN/documents/Media_Press_Releases/2014/ASH2014_cal.pdf

Also Erika A Eksioglu associated with Moffitt Cancer Center (same as Peregrine KOL Dmitry Gabrilovich) and Deborah Stephens associated with Ohio State Comp. Cancer Center ( same as Peregrine KOL David Carbone).